Clinical Trial Update: Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating MK-4827 in combination with temozolomide to assess safety and preliminary efficacy in adults with advanced cancers, including glioblast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme
• Melanoma

Drugs mentioned

• MK-4827
• Temozolomide (Temozolomide)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Recurrence of Solid Tumor, Glioblastoma Multiforme | Phase 1 | Status: COMPLETED